Early Urinary Catheter Removal Following Pelvic Colorectal Surgery: A Prospective, Randomized, Noninferiority Trial

Dis Colon Rectum. 2018 Oct;61(10):1180-1186. doi: 10.1097/DCR.0000000000001206.

Abstract

Background: Because of the potential increased incidence of acute urinary retention, optimal timing of urinary catheter removal after major pelvic colorectal surgery remains unclear.

Objective: This study aims to compare the incidence of urinary retention following early catheter removal on postoperative day 1 vs standard catheter removal on day 3.

Design: This is a randomized, noninferiority trial.

Setting: This study was conducted at an urban teaching hospital.

Patients: Patients undergoing colorectal surgery below the peritoneal reflection were selected.

Interventions: A 1:1 randomization to early or standard catheter removal was performed. Patients in the early arm were administered an α-antagonist (prazosin 1 mg oral) 6 hours before catheter removal.

Main outcome measures: The primary outcome measured was the incidence of acute urinary retention.

Results: One hundred forty-two patients were randomly assigned to early (n = 71) or standard (n = 71) catheter removal. Mean age was 44.8 ± 16.9 years, and the study cohort included 54% men. The most common operations were IPAA (66%) and low anterior resection (18%). The overall rate of retention was 9.2% (n = 13), with no difference between early (n = 6; 8.5%) or standard (n = 7; 9.9%) catheter removal (RR, 0.86; 95% CI, 0.30-2.42). The risk difference was -1.4% (95% CI, -8.3 to 11.1), confirming noninferiority. The rate of infection was significantly lower in early vs standard catheter removal (0% vs 11.3%; p = 0.01). Length of stay was significantly shorter after early vs standard catheter removal (4 days, interquartile range = 3-6 vs 5 days, interquartile range = 4-7; p = 0.03).

Limitations: Patients and investigators were not blinded; a nonselective oral α-antagonist was used.

Conclusions: Following pelvic colorectal surgery, early urinary catheter removal, when combined with the addition of an oral α-antagonist, is noninferior to standard urinary catheter removal and carries a lower risk of symptomatic infection and shorter hospital stay.

Clinical trial registration: http://www.clinicaltrials.gov (NCT01923129). See Video Abstract at http://links.lww.com/DCR/A738.

Publication types

  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Acute Disease
  • Adrenergic alpha-1 Receptor Antagonists / administration & dosage
  • Adult
  • Colorectal Surgery / adverse effects*
  • Device Removal / adverse effects*
  • Female
  • Humans
  • Incidence
  • Length of Stay
  • Male
  • Middle Aged
  • Outcome Assessment, Health Care
  • Postoperative Period
  • Prazosin / administration & dosage
  • Prospective Studies
  • Urinary Catheters / adverse effects*
  • Urinary Retention / epidemiology*
  • Urinary Retention / etiology
  • Urinary Tract Infections / epidemiology*
  • Urinary Tract Infections / etiology

Substances

  • Adrenergic alpha-1 Receptor Antagonists
  • Prazosin

Associated data

  • ClinicalTrials.gov/NCT01923129